Studie Über Das Leukämogene Potential Der Hoxb4-Deltaprolin
Total Page:16
File Type:pdf, Size:1020Kb
Aus der Medizinischen Klinik und Poliklinik III Klinikum Großhadern / Ludwig-Maximilians-Universität München Vorstand: Prof. Dr. med. Wolfgang Hiddemann Studie über das leukämogene Potential der Hoxb4-ΔProlin Mutante in einem murinen Knochenmarkstransplantationsmodell und den Effekt der Hemmung von Histondeacetylasen in vitro und in vivo Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität in München vorgelegt von Monica Cusan aus Portogruaro, Italien Jahr 2012 Mit Genehmigung der Medizinischen Fakultät der Universität München Berichterstatter: Prof. Dr. med. Christian Buske Mitberichterstatter: Priv. Doz. Dr. Irmela Jeremias Priv. Doz. Dr. Michael Albert Prof. Dr. Christian P. Sommerhoff Prof. Dr. Stefan Endres Dekan: Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR Tag der mündlichen Prüfung: 04.10.2012 From the Department of Medicine III University Hospital Großhadern, Ludwig-Maximilians-University Munich Director: Prof. Dr. med. Wolfgang Hiddemann Investigation of the leukemogenic potential of the Hoxb4- ΔProline mutant in a murine bone marrow transplantation model and the effect of the histonedeacetylase inhibition in vitro and in vivo Thesis Submitted for a Doctoral Degree in Human Medicine at the Faculty of Medicine, Ludwig-Maximilians-University in Munich submitted by Monica Cusan from Portogruaro, Italy Year 2012 With permission from the Faculty of Medicine University of Munich Supervisor/Examiner: Prof. Dr. med. Christian Buske Co-Examiner: Priv. Doz. Dr. Irmela Jeremias Priv. Doz. Dr. Michael Albert Prof. Dr. Christian P. Sommerhoff Prof. Dr. Stefan Endres Dean: Prof. Dr. med. Dr. hc. M. Reiser, FACR, FRCR Date of Oral Exam: 04.10.2012 Index 1. Introduction........................................................................................................................................ 1 1.1. Hematopoiesis.............................................................................................................................. 1 1.1.1 The hematopoiesis ................................................................................................................. 1 1.1.2.The hematopoietic hierarchy .................................................................................................. 2 1.1.3. Stem cells and hematopoietic stem cells ............................................................................. .3 1.2. Leukemia ...................................................................................................................................... 7 1.2.1 Acute leukemia....................................................................................................................... 7 1.2.2 Leukemic stem cells ............................................................................................................. 10 1.2.3 Molecular pathways leading to leukemia ............................................................................. 11 1.2.4 Chromosomal translocations in AML.................................................................................... 14 1.3. The homeobox genes................................................................................................................. 15 1.3.1 The homeobox genes in hematopoiesis and leukemogenesis ............................................ 15 1.3.2 Cofactors of the HOX genes ................................................................................................ 20 1.3.3 Hoxb4 ................................................................................................................................... 22 1.3.3.1 Hoxb4 in the hematopoiesis .......................................................................................... 25 1.3.3.2 Hoxb4 as amplification tool of HSCs............................................................................. 26 1.3.3.3 The proline-rich domain................................................................................................. 28 1.3.3.4 The downstream targets of Hoxb4 ................................................................................ 30 1.4. Epigenetic changes in cancer..................................................................................................... 31 1.4.1 Histone deacetylases (HDACs)............................................................................................ 32 1.4.2 Histone deacetylases inhibitors (HDACi) ............................................................................. 34 1.5. The murine bone marrow transplantation model of leukemia .................................................... 35 1.6. Aim of the study.......................................................................................................................... 36 2. Materials ........................................................................................................................................... 39 2.1. Mice and related reagents and equipment ................................................................................. 39 2.2. Mammalian cell lines and prokaryotic cells ................................................................................ 39 2.3. Oligonucleotides ......................................................................................................................... 40 2.4. Plasmids, genes and proteins .................................................................................................... 41 2.5. Antibodies ................................................................................................................................... 42 2.6. Reagents, media and apparatus ................................................................................................ 43 2.6.1 Molecular biology.................................................................................................................. 43 2.6.2 Cell and tissue culture .......................................................................................................... 45 2.6.3 Miscellaneous....................................................................................................................... 47 2.6.4 Software ............................................................................................................................... 48 3. Methods............................................................................................................................................ 49 3.1. Mice maintenance....................................................................................................................... 49 3.2. Cloning of constructs .................................................................................................................. 49 3.3. Mutagenesis of Hoxb4 constructs .............................................................................................. 49 3.4. Transient transfection of packaging cell lines for VCM production ............................................ 50 3.5. Preparation of high titer stable virus-producing cell lines........................................................... 50 3.6. Titration of the retroviral conditioned medium (VCM)................................................................. 51 3.7. Culture conditions of cell lines and murine bone marrow cells................................................... 51 Index 3.8. Retroviral transduction of primary bone marrow cells.................................................................51 3.9. Bone marrow transplantation and assessment of mice .............................................................53 3.10. FACS analysis of murine primary cells ....................................................................................54 3.11. In vitro and ex vivo functional assays of murine BM cells: proliferation and CFC assay .........55 3.12. Cytospin preparation and Wright-Giemsa staining ..................................................................55 3.13. Histological and immunohistochemical analysis ......................................................................55 3.14. Delta-colony forming unit-spleen (∆CFU-S) assay ..................................................................56 3.15. Quantification of competitive repopulating units (CRU-assay) ................................................56 3.16. Total RNA / genomic DNA isolation and cDNA preparation ...................................................57 3.17. Southern blot.............................................................................................................................57 3.18. Integration analysis: bubble LM-PCR ......................................................................................58 3.19. Western blot .............................................................................................................................58 3.20. Immunoprecipitation..................................................................................................................60 3.21. Polymerase chain reactions .....................................................................................................61 3.22. Immunostaining and confocal laser microscopy scanning fluorescence microscopy...............61 3.23. Statistical analysis.....................................................................................................................62 4. Results ..............................................................................................................................................63